Neuromyotonia with polyneuropathy, prominent psychoorganic syndrome, insomnia, and suicidal behavior without antibodies: a case report
Language English Country Great Britain, England Media electronic
Document type Case Reports, Journal Article
PubMed
25943238
PubMed Central
PMC4436852
DOI
10.1186/s13256-015-0581-0
PII: 10.1186/s13256-015-0581-0
Knihovny.cz E-resources
- MeSH
- Adrenergic alpha-Antagonists therapeutic use MeSH
- Antidepressive Agents, Second-Generation therapeutic use MeSH
- Electromyography MeSH
- Immunoglobulins, Intravenous therapeutic use MeSH
- Isaacs Syndrome diagnosis drug therapy psychology MeSH
- Humans MeSH
- Mianserin analogs & derivatives therapeutic use MeSH
- Mirtazapine MeSH
- Suicide, Attempted * MeSH
- Polyneuropathies drug therapy MeSH
- Sleep Initiation and Maintenance Disorders drug therapy MeSH
- Aged MeSH
- Venlafaxine Hydrochloride therapeutic use MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Adrenergic alpha-Antagonists MeSH
- Antidepressive Agents, Second-Generation MeSH
- Immunoglobulins, Intravenous MeSH
- Mianserin MeSH
- Mirtazapine MeSH
- Venlafaxine Hydrochloride MeSH
INTRODUCTION: Peripheral nerve hyperexcitability disorders are characterized by constant muscle fiber activity. Acquired neuromyotonia manifests clinically in cramps, fasciculations, and stiffness. In Morvan's syndrome the signs of peripheral nerve hyperexcitability are accompanied by autonomic symptoms, sensory abnormalities, and brain disorders. CASE PRESENTATION: A 70-year-old Caucasian man developed, in the course of 3 months, polyneuropathy with unpleasant dysesthesia of lower extremities and gradually increasing fasciculations, muscle stiffness and fatigue. Subsequently, he developed a prominent insomnia with increasing psychological changes and then he attempted a suicide. Electromyography confirmed a sensory-motor polyneuropathy of a demyelinating type. The findings included fasciculations as well as myokymia, doublets and multiplets, high frequency discharges, and afterdischarges, following motor nerve stimulation. No auto-antibodies were found either in his blood or cerebrospinal fluid. Magnetic resonance imaging of his brain showed small, unspecific, probably postischemic changes. A diagnosis of Morvan's syndrome was confirmed; immunoglobulin (2g/kg body weight) was applied intravenously, and, subsequently, carbamazepine 2 × 200 mg, venlafaxine 150 mg, and mirtazapine each night were prescribed. His sleep improved, suicidal tendencies stopped, less fasciculations occurred, and muscle hypertonia also improved. Hyperexcitation also partially remitted including the electromyography finding. CONCLUSIONS: We described here the case of a patient with Morvan's syndrome; his case is rare because of severe psychical changes with a suicide attempt, short admission to a psychiatric ward, prominent electromyographic changes, and because antibodies were not detected. After therapy with immunoglobulins followed by corticosteroids with sodium channel blocker, his motor, autonomic, psychical signs and symptoms, and electromyography changes substantially improved.
See more in PubMed
Gutmann L, Gutmann L. Myokymia and neuromyotonia 2004. J Neurol. 2004;251:138–42. doi: 10.1007/s00415-004-0331-5. PubMed DOI
Loukaides P, Schiza N, Pettingil P, Palazis L, Vounou E, Vincent A. Morvan’s syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex. J Neurol Sci. 2012;312:52–6. doi: 10.1016/j.jns.2011.08.024. PubMed DOI
Rinaldi C, Russo CV, Filla A, De Michele G, Marano E. Course and outcome of voltage-gated potassium channel antibody negative Morvan’s syndrome. Neurol Sci. 2009;30:237–9. doi: 10.1007/s10072-009-0041-y. PubMed DOI
Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, et al. Morvan syndrome: Clinical and serological observations in 29 cases. Ann Neurol. 2012;72:241–55. doi: 10.1002/ana.23577. PubMed DOI
Merchut MP. Management of voltage-gated potassium channel antibody disorders. Neurol Clin. 2010;28:941–59. doi: 10.1016/j.ncl.2010.03.024. PubMed DOI